Microbial Diversity of Pancreatic Diseases
NCT03809247 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 330
Last updated 2023-06-15
Summary
This study plans to analyze the digestive flora structure of the group of patients with pancreatic cancer.
The investigators compared the microflora of pancreatic cancer with other pancreatic diseases and healthy people,in order to obtatin the information of microbial community difference among the different groups. Finally,the investigators hope to identify the potential biomarker and pathogenic mechanisms that causes the onset and progression of pancreatic diseases.
Conditions
- Pancreatic Cancer
- Pancreatic Disease
Interventions
- OTHER
-
have no any intervention
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Principal Investigators
-
Wei WANG, Dr. · Ruijin Hospital
Eligibility
- Min Age
- 3 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-02-01
- Primary Completion
- 2024-07-30
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729 ·Status: UNKNOWN
-
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer
NCT05168254 ·Status: UNKNOWN
-
Microbiome Characterization in Fatty Pancreas
NCT06938646 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient
NCT02338752 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
NCT05168527 ·Status: UNKNOWN ·Phase: PHASE2
-
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
NCT03432624 ·Status: UNKNOWN
-
Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
NCT06960122 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
NCT04525209 ·Status: UNKNOWN
-
Oral Microbiome and Pancreatic Cancer
NCT03302637 ·Status: COMPLETED
-
Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer
NCT03977272 ·Status: COMPLETED ·Phase: PHASE2
-
In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer
NCT05842187 ·Status: UNKNOWN ·Phase: NA
-
Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer
NCT00897741 ·Status: COMPLETED
-
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
NCT03983057 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05969171 ·Status: RECRUITING ·Phase: PHASE2
-
Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
NCT06655233 ·Status: RECRUITING
-
Clinical Trial for Advanced or Metastatic Pancreatic Cancer
NCT06255912 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
NCT05185869 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
NCT05438797 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT03929094 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
NCT05908747 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Early Detection of PDAC in Patients With Chronic Pancreatitis
NCT07104864 ·Status: COMPLETED
-
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT04975217 ·Status: SUSPENDED ·Phase: EARLY_PHASE1
-
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
NCT06595160 ·Status: RECRUITING
-
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326 ·Status: RECRUITING ·Phase: PHASE2
-
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889 ·Status: RECRUITING ·Phase: PHASE1/PHASE2